LifeCycle Pharma to start Phase II trials of hepatitis drug

[Guest guest]

LifeCycle Pharma to start Phase II trials of hepatitis drug

COPENHAGEN (Thomson Financial) - LifeCycle Pharma said it has initiated Phase II clinical trials of LCP-Tacro for the treatment of autoimmune hepatitis (AIH), also referred to as chronic active hepatitis, a disease which causes a person's body to reject its own liver.

The clinical trial is expected to enroll up to 60 patients in up to 12 centres throughout the US and Canada and the first results are expected to be reported in the first half of 2009.

The company wants LCP-Tacro to be the first FDA-approved drug indicated for the treatment of AIH.

Hans.Chumakonde@...

http://www.forbes.com/markets/feeds/afx/2008/01/02/afx4485947.html